Endometrial cancer is the most common genital cancer in high‐resource countries. Treatment is essentially surgical, but the role of lymphadenectomy in the treatment of low‐stage and low‐grade tumors has not been defined. Although no tumor factor...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O113120281
2020년
-
0020-7292
1879-3479
SCIE;SCOPUS
학술저널
265-268 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
Endometrial cancer is the most common genital cancer in high‐resource countries. Treatment is essentially surgical, but the role of lymphadenectomy in the treatment of low‐stage and low‐grade tumors has not been defined. Although no tumor factor...
Endometrial cancer is the most common genital cancer in high‐resource countries. Treatment is essentially surgical, but the role of lymphadenectomy in the treatment of low‐stage and low‐grade tumors has not been defined. Although no tumor factors have been validated for use as preoperative prognostic markers of endometrial cancer at yet, human epididymis protein 4 (HE4) has received much interest as a potential diagnostic and prognostic tumor marker. Since 2008, several studies have explored its utility in the management of endometrial cancer: HE4 may be a useful preoperative prognostic marker because it is associated with lymphatic metastasis and other unfavorable factors in endometrial cancer. In addition, some studies have explored a HE4 cutoff value to classify patients according to lymph node involvement. HE4 might be beneficial as a serum marker that helps clinicians in the decision‐making algorithm for treatment of endometrial cancer, enabling them to perform individualized operations and decrease the adverse effects of unnecessary surgery.
As a preoperative tumor marker, human epididymis protein 4 (HE4) seems to be useful for managing endometrial cancer and is associated with lymphatic metastasis.
Towards a global consensus on GDM diagnosis: Light at the end of the tunnel?
FIGO statement on minimally invasive surgery in cervical cancer